TC BIOPHARM HLDGS PLC WT PUR S (TCBWF): Financials
Fiscal year ended December 31, 2024
Income statement, cash flow and balance sheet figures for TC BIOPHARM HLDGS PLC WT PUR S (TCBWF), read directly from the XBRL data the company files with the SEC. Net loss was $15.3M.
3 fiscal years of history are available, back to 2022.
Frequently asked questions
How much revenue does TCBWF make?
Revenue for TC BIOPHARM HLDGS PLC WT PUR S comes from the company's SEC XBRL filings. When the company reports a tagged revenue figure it appears on this page.
Is TCBWF profitable?
TC BIOPHARM HLDGS PLC WT PUR S was unprofitable over the most recent fiscal year, with a net loss of $15.3M.
Where does this financial data come from?
Every figure on this page is read from the company's own SEC 10-Q and 10-K filings. Nothing is estimated by a third party. Quarterly figures a company does not file separately (most commonly the fourth quarter) are derived by subtracting the reported year-to-date quarters from the full fiscal year, and are labelled as derived.
What is the difference between quarterly, annual and TTM?
Quarterly shows each three-month fiscal period on its own. Annual shows the full fiscal year as filed in the 10-K. TTM (trailing twelve months) sums the last four reported quarters, which is the most current annualised view between 10-K filings.